Merck Stock Forecast for 2023 - 2025 - 2030
Updated on 05/21/2024
Merck Stock Forecast and Price Target
The average price target of $143.00 for Merck's stock set by eleven distinguished analysts in recent weeks would represent a potential upside of approximately 9.17% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $155.00 and a low estimate of $118.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.
9.17% Upside
Merck Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Merck's Price has decreased from $80.78 to $0.00 – a 100.00% drop! The next year looks promising for Merck, with analysts predicting Fair Value of $112.74 – an increase of 100.00%. Over the next seven years, experts anticipate that Merck's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$783.18 | Buy/Sell | $636.99 | 12.04% |
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$151.27 | Buy/Sell | $174.55 | 12.38% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.53 | Buy/Sell | $32.87 | 6.91% |
VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$445.87 | Buy/Sell | $457.59 | 2.94% |
REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$987.27 | Buy/Sell | $961.26 | 6.35% |
Merck Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Merck's Revenue has grown, increasing from $47.99B to $60.12B – a growth of 25.26%. The next year, 16 experts forecast that Merck's Revenue will decrease by 3.38%, reaching $58.09B. In 2030, professionals predict that Merck's Revenue will decrease by 14.39%, reaching $51.46B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$43.36 | Buy/Sell | $58.15 | 24.54% |
ZTS Stock Forecast | Zoetis | Outperform |
18
|
$174.39 | Buy/Sell | $220.47 | 24.43% |
ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$150.24 | Buy/Sell | $245.24 | 44.77% |
Merck Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Merck's Dividend per Share has grown by 19.67%, from $2.44 to $2.92. For the next year, analysts are expecting Dividend per Share to reach $3.27 – an increase of 11.99%. Over the next seven years, experts predict that Dividend per Share will grow by 9.59%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAX Stock Forecast | Baxter International Inc | Hold |
17
|
$35.02 | Buy/Sell | $44.86 | 25.64% |
VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.07 | Buy/Sell | $11.73 | 8.40% |
UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$274.67 | Buy/Sell | $284.08 | 9.22% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CTLT Stock Forecast | Catalent | Hold |
15
|
$55.00 | Buy/Sell | $49.29 | 15.45% |
CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$60.60 | Buy/Sell | $87.92 | 55.12% |
IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$38.72 | Buy/Sell | $55.60 | 54.96% |
Merck EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Merck's EBITDA has fallen from $19.07B to $8.30B – a 56.49% decrease. For next year, analysts predict EBITDA of $26.32B, which would mean an increase of 217.18%. Over the next seven years, experts predict that Merck's EBITDA will grow at a rate of 119.92%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BCPC Stock Forecast | Balchem | Outperform |
18
|
$154.39 | Buy/Sell | $145.00 | 6.87% |
MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$232.10 | Buy/Sell | $315.92 | 66.31% |
NEOG Stock Forecast | Neogen | Outperform |
16
|
$13.67 | Buy/Sell | $37.00 | 24.36% |
Merck EBIT Forecast for 2023 - 2025 - 2030
Merck's EBIT has decreased In the last three years, from $15.71B to $4.57B – a 70.95% drop. For next year, analysts predict EBIT of $24.18B, which would mean an increase of 429.70%. Over the next seven years, experts predict that Merck's EBIT will grow at a rate of 327.40%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$28.88 | Buy/Sell | $35.67 | 38.50% |
INDV Stock Forecast | Indivior PLC | Buy |
14
|
£13.33 | Buy/Sell | £28.89 | 132.03% |
TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$16.48 | Buy/Sell | $29.44 | 109.34% |
Merck EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Merck's EPS has decreased from $5.94 to $0.00 – a 100.00% drop! The next year looks promising for Merck, with analysts predicting EPS of $8.29 – an increase of 100.00%. Over the next seven years, experts anticipate that Merck's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$43.07 | Buy/Sell | $69.00 | 43.95% |
CPRX Stock Forecast | Catalyst Pharmaceuticals | Buy |
16
|
$16.92 | Buy/Sell | $26.20 | 53.66% |
SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$28.77 | Buy/Sell | $41.00 | 42.51% |